The central nervous system is physiologically separated from other body compartments by the blood-brain barrier (BBB) 
.
Immunohistochemistry studies co-localized Angiopep-2 with astrocytes and neurons after in situ brain perfusion or IV bolus injection. The binding, uptake and transport of Angiopep-2 evaluated in immortalized rat brain endothelial cells (RBE4) demonstrated a role for LRP-1 in its active transport. Results from these studies show that the EPiC platform may have significant potential for the development of other new neurotherapeutics.

Materials and methods
Reagents
Peptides 
Histological analysis and immunohistochemistry
RBE4 cell lines
RBE4 were grown as previously described [1] . Briefly (Fig. 2A,  upper panel) , whereas Cy5.5Angiopep-7 fluorescence was below detectable levels ( Fig. 2A, lower panel) .
After a 2-min. in situ brain perfusion, fluorescence derived from Cy5.5Angiopep-2 was observed in both brain capillaries and in the brain parenchyma (Fig. 2B, upper panels) and was higher after a 10-min. perfusion. Cy5.5Angiopep-7 fluorescence was detectable only in intravascular spaces, with no fluorescence detected in the brain parenchyma, after either a 2-or 10-min. perfusion (Fig. 2B lower panels) .
Immunofluorescence labelling studies on brain sections with glial marker GFAP (Fig. 2C and D) and neuronal nuclei-selective marker NeuN (Fig. 2E and F) were also performed. Results showed that Cy5.5Angiopep-2 fluorescence was found in the brain parenchyma within the immunoreactive region positively stained for both markers (Fig. 2C and E) [21] . In contrast, Cy5.5Angiopep-7 was undetected under the same conditions in the brain regions labelled with GFAP and NeuN ( Fig. 2D and E) . (Fig. 3A) . The antibody detected Angiopep-2 in brain homogenate spiked with Angiopep-2 (2 g) at the expected molecular weight and with no apparent cross-reactivity to other brain proteins (Fig. 3B) .
Immunohistochemical detection of Angiopep-2 in brain
Using this pAb, Angiopep-2 was detected in brain parenchyma of mice after a 10-min. in situ brain perfusion at 37ЊC with peptide (4 M) followed by a 60 sec. washout with Krebs buffer (Fig. 3C ), but not in control animals perfused with Krebs buffer alone (Fig. 3E) . To determine whether similar uptake occurred after IV bolus injection, mice were injected into the tail vein with 20 mg/kg Angiopep-2 or saline, and, after a 60 min. uptake period, were perfused with cold saline to remove excess peptide from the blood. Subsequent immunohistochemistry performed on fixed brain sections showed that Angiopep-2 was present in the brain parenchyma (Fig. 3D) , but immunoreactivity levels were lower than those observed after in situ perfusion. (Fig. 4B, insert) (Fig. 4D) .
Transport mechanism of Angiopep-2 into brain endothelial cells
as a function of unlabelled concentration of Angiopep-2 (Fig. 4B). The non-specific uptake measured in the presence of the highest concentration of unlabelled Angiopep-2 was subtracted, and results were expressed in terms of Angiopep-2 (pmol/10 6 cells/min.) as a function of total Angiopep-2 concentration
Effect of charge on Angiopep transport
It has been demonstrated that the polybasic nature of some LRP-1 ligands affects their affinity to the receptor [22] . (Fig. 5B) . [16] . A primary objective of the current study was to improve our understanding of the biodistribution and cellular localization patterns of Angiopep-2 and Angiopep-2-derived agents after systemic injection. In previous studies [16, 23] , brain distribution of Angiopep-2 was assessed after in situ brain perfusion using a physical separation technique [24] The observed localization results are consistent with the underlying biology of the system. Thus, the broad distribution pattern likely reflects the fact that capillary density in the cerebrum is extraordinarily high, with virtually every neuron perfused by its own vessel [25] . Additionally, LRP-1, which participates in transporting Angiopep-2 across the BBB, is abundantly expressed on brain capillaries [26, 27] . The immunofluorescence results with GFAP and NeuN suggest that after passing through the BBB, Angiopep-2 could reach neurons and astrocytes. Both of these parenchymal cell types are known to express LRP-1 [28] [29] [30] [31] [32] [8] [9] [10] [11] [12] 33] [36] . Nonetheless, the capacity for Angiopep-2 transport may be greater than these other proteins [37] [22, 43] . Cationic polyamines like protamine are also known to affect LRP-1 binding to its ligands [44] . [5, 53, 54] [55, 56] , and it has been argued that one of the main limitations preventing their development has been the BBB [4, 5, 53, 54] . The results presented here and in earlier studies [23, 40] suggest that the EPiC platform may have significant utility in overcoming this constraint on the development of novel neurotherapeutics.
The results obtained for two other highly-charged peptides indicated that the total brain volume of distribution increased as a function of the charge. However, this greater volume of distribution was primarily the consequence of a stronger interaction of highly positively-charged peptides with the negatively charged brain vessels, as indicated by the ratio between the volumes of distribution measured for the brain parenchyma (after capillary depletion) and for the total brain (P/B)
Discussion
The data presented here further characterize a new drug-development platform designed to facilitate the isolation of neurotherapeutics with increased brain penetration. The EPiC platform is based on the Angiopep-2 peptide, which is transported across the © 2009 The Authors Journal compilation © 2010 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
